Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Continues to Build Lab Informatics Portfolio with Labtronics Acquisition

Premium

PerkinElmer announced this week that it has acquired Ontario, Canada-based Labtronics to enhance its laboratory informatics portfolio.

PE's most recent catch, the latest in a string of recent informatics purchases, markets the Nexxis electronic laboratory notebook, Nexxis iLAB laboratory automation platform, and LimsLink lab integration software platform.

The announcement follows PE's purchase of Geospiza for an undisclosed amount earlier this month (BI 05/06/2011) and its March acquisition of CambridgeSoft and ArtusLabs, which also offers an electronic laboratory notebook. The combined purchase price for those two privately held firms was $220 million (BI 03/25/2011).

PerkinElmer did not disclose the financial terms of the Labtronics acquisition.

PE said that the new additions from Labtronics extend its ELN and data integration software offerings into laboratories that follow strict routine procedures, such as regulated and non-regulated quality assurance and control; late stage product- or method-development laboratories; and environmental and food testing labs.

Labtronics tools can be applied to any procedure-based problem, including laboratory analysis, equipment calibration and validation, and cleaning validation, PE said.

Dusty Tenney, president of analytical sciences and laboratory services at PerkinElmer, said the "acquisition successfully positions PerkinElmer as the only technology provider able to deploy an optimized ELN solution across a global customer's entire value chain, from research to manufacturing."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more